Company Profile

Industry Sector: Diagnostics

Company Overview: mBio Diagnostics aims to be a leader in providing instrumentation for point-of-care testing. Our initial aim is within infectious diseases, particularly HIV and other diseases with major public health significance. The platform is low cost, highly sensitive, and adaptable to a wide variety of measurements, ranging from serology to direct hybridization to cellular analysis. Particular emphasis has been placed on HIV and key co-infections, such as hepatitis and TB. mBio Diagnostics is a division of Precision Photonics Corporation, a cash-flow positive leader in the field of ultra-sensitive and ultra-precise laser technologies—a true distinguishing factor relative to most start-up biomedical technology ventures. We plan to spin off mBio when the time is appropriate.

Target Market(s): Two broad markets: World health (HIV and co-infections), and clinics and physicians office labs in developed markets, where a broad menu will be critical.

Key Value Drivers

Technology*: The SnapEsi technology—consisting of an advanced evanescent waveguide concept, specialty fluorescent filters, low-cost CMOS imaging, laser illumination, and proprietary sample preparation and flow features—is a complete system for simple assays with ultra-sensitive detection that can be run at the point of care. We have shown efficacy across a broad set of applications: serology, cellular analysis, and direct hybridization.

Competitive Advantage: The complete package is an innovative combination of well proven technologies in a proprietary and well protected format, with more than 40 US and international patents protecting the core concepts. Efficacy is supported by initial clinical data. To our knowledge, no other lab-on-a-chip system has advanced as far as our system has as quickly, demonstrating the attractive simplicity and ease of scale up.

Plan & Strategy: We plan to ultimately license the technology. To this end, we are demonstrating efficacy across a broad range of applications, and driving a select set of indications (including HIV) to FDA approval. This shows the broad efficacy, and the ability to gain approval on a Class 3 indication.

*Technology funded by the NIAID and being commercialized under the NIH-CAP

Management

Leadership:
Chris Myatt, Ph.D., Founder and CEO
Mike Lochhead, Ph.D., Vice President
Jeff Ives, Ph.D., Director of Assay Development and Regulatory Compliance
Kurt Vogel, Ph.D., Director of Hardware Development
Nick Colella, Ph.D., Director of Licensing Strategy

Scientific Advisors and Collaborators:
Robert Schooley, MD, Professor and Head, Division of Infectious Disease, UCSD
Costance Benson, MD, Professor, UCSD, and Chair & PI, NIH/NIAID Adult AIDS Clinical Trials Group
Sharon Reed, MD, Professor and Director, UCSD Medical Center Microbio. Lab.
Roberto Badaro, MD, Professor, Fed. Univ. of Bahia (Brazil)
James Herron, Ph.D., Associate Professor, Univ. of Utah

Product Pipeline

<table>
<thead>
<tr>
<th>HIV Serology</th>
<th>Pre-Clin Devel</th>
<th>Clinical Validation</th>
<th>Clinical Trial</th>
<th>Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Completed 2008</td>
<td>Mid 2010</td>
<td>Late 2010</td>
<td>PMA 2011</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HIV CD4</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2012</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HIV Viral Load</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
</tr>
</thead>
</table>